Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

Hemophilia A is a genetic bleeding disorder caused by a deficiency in clotting factor VIII. Treatment focuses on managing bleeding episode symptoms with clotting factor replacement therapy, ...

A single dose of intravenous (IV) iron dextran is the most cost-effective treatment for women with heavy menstrual bleeding ...

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasis Grifols (GRFS) surgical bleeding ...

Even as biomedical engineer Anirban Sen Gupta refines artificial platelets to stem traumatic bleeding, he and his colleagues are seeking new uses for their synthetic solution. The latest application ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...

A rapid blood test could speed treatment for people who have suffered a stroke related to brain bleeding, a new study says. Stroke victims with brain bleeds have nearly seven times higher blood levels ...

Hemophilia A is a rare, inherited condition that prevents your blood from clotting the way it should. People with hemophilia A do not make enough of a protein called factor VIII, which normally works ...